Carcinoma of Unknown Primary withEML4-ALKFusion Response toALKInhibitors
Authors:
Open Access
- 24 January 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 24 (4) , 449-454
Abstract
With the advent of next-generation sequencing (NGS) and precision medicine, investigators have determined that tumors from different tissue sources that have the same types of genetic mutations will have a positive response to the same targeted therapy. This finding has prompted us to seek potential therapeutic targets for patients with carcinoma of unknown primary (CUP) using NGS technology. Here, we reported a case of a woman with CUP resistance to chemotherapy. We detected 450 cancer-related gene alterations using three metastatic tumor specimens and found the presence of EML4 exon13 and ALK exon20 fusion. The tumor did respond to crizotinib, a first-generation ALK inhibitor. When her tumor progressed, circulating tumor DNA detection revealed ALK L1196 M and G1269A mutation resistance to crizotinib, but she had a response to brigatinib. This case revealed that NGS technology used to detect the genetic alterations in patients with CUP might be a reliable method to find potential therapeutic targets, although the primary lesion could not always be confirmed.Key Points: This case exemplifies responsiveness to ALK inhibitor in carcinoma of unknown primary (CUP) with EML4-ALK fusion. Next-generation sequencing is an important diagnostic tool to find potential therapeutic targets in CUP. Liquid biopsy may be useful to provide critical information about resistance mechanisms in CUP to guide sequential treatment decision with targeted therapy.Keywords
Funding Information
- Key Research Development Program of Zhejiang Province (2018C03018)
- National Natural Science Foundation of China (81472346)
This publication has 27 references indexed in Scilit:
- IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in gliomaNeuro-Oncology, 2013
- Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practiceAnnals of Oncology, 2011
- Validation and Reproducibility of a Microarray-Based Gene Expression Test for Tumor Identification in Formalin-Fixed, Paraffin-Embedded SpecimensThe Journal of Molecular Diagnostics, 2011
- The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase geneEuropean Journal of Cancer, 2010
- A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor geneGenes, Chromosomes and Cancer, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapyExpert Review of Anticancer Therapy, 2009
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research NetworkJournal of Clinical Oncology, 2007
- A Quantitative Reverse Transcriptase-Polymerase Chain Reaction Assay to Identify Metastatic Carcinoma Tissue of OriginThe Journal of Molecular Diagnostics, 2006